Table 2 Consumption trends of antiasthmatic drugs in INN
From: Trends in the use of antiasthmatic medications in Morocco (1999–2010)
Classes/INN | ATC | DDD/1000H/D | ||
|---|---|---|---|---|
1999 | 2006 | 2010 | ||
Short-acting inhaled Beta-2-mimetic | ||||
Salbutamol | R03AC02 | 1.70 | 3.42 | 3.94 |
Terbutaline | R03AC03 | 0.12 | 0.04 | 0.06 |
Fenoterol | R03AC04 | 0.06 | - | - |
Pirbuterol | R03AC08 | 0 | - | - |
Orciprenaline | R03AB03 | 0.06 | - | - |
Systemic Beta-2-mimetic | ||||
Salbutamol | R03CC02 | 0.23 | 0.31 | 0.33 |
Terbutaline | R03CC03 | 0.04 | 0.03 | 0.02 |
Long-acting inhaled Beta-2-mimetic | ||||
Formeterol | R03AC12 | 0.01 | 0.07 | 0.04 |
Salmeterol | R03AC13 | 0.02 | - | - |
Association Beta-2-mimetic /Glucocorticosteroids | ||||
Fluticasone + Salmeterol | R03AK06 | - | 1.08 | 6.05 |
Budesonide + Formeterol | R03AK07 | - | 0.24 | 2.47 |
Inhaled Glucocorticosteroids alone | ||||
Bedomethasone | R03BA01 | 0.65 | 0.95 | 1.01 |
Budesonide | R03BA02 | 0.03 | 0.01 | |
Fluticasone | R03BA05 | 0.03 | 0.15 | 0.12 |
Injectable Xanthines | ||||
Theophylline | R03DA04 | 0.89 | 0.43 | 0.34 |
Diprophylline + Tiemonium iodure | R03DA51 | 0.05 | 0.05 | 0,.05 |